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Michelle F. Dennis,2 Patrick S. Calhoun,1–3,7 Angela C. Kirby,1,3 and Jean C. Beckham1–3
The perspectives of patients with posttraumatic stress disorder (PTSD) on genetic research have not yet been
investigated in the genetics research literature. To provide a basis for research on attitudes toward genetic
research in PTSD, we surveyed the U.S. Military Afghanistan/Iraq-era veterans with PTSD and their social
support companions to investigate the attitudes and knowledge about genetics and genetic testing. One hundred
forty-six veterans (76 with PTSD and 70 without PTSD) participated in this study. Each veteran participant had a
corresponding companion (primarily spouses, but also relatives and friends) who they identified as a primary
member of their social support network. Participants and companions completed self-report measures on
knowledge of genetics and attitudes toward genetic testing for PTSD. Results indicated that, relative to veterans
without PTSD, veterans with PTSD had similar levels of genetic knowledge, but less-favorable attitudes toward
genetic testing. Differences persisted after controlling for age and genetics knowledge. No differences between
companions of those with and without PTSD were observed. Results suggest that the perspective of those with
PTSD regarding genetic testing is in need of further investigation, especially if potentially beneficial genetic
testing for PTSD is to be utilized in the target population.
Introduction
Although most individuals will be exposed to a trau-matic event over the course of their lifetimes (Breslau
and Kessler, 2001), only a fraction will subsequently develop
posttraumatic stress disorder (PTSD), suggesting the possi-
bility of a genetic contribution. In fact, more than 30% of the
variance for PTSD risk is attributed to genetic factors, as evi-
denced by family and twin-heritability studies (Lyons et al.,
1993; Sack et al., 1995; Yehuda et al., 2001; Stein et al., 2002;
Kremen et al., 2012). More than 30 candidate gene studies have
been performed [for reviews see Cornelis et al. (2010) and
Yehuda et al. (2011)]. These studies have produced inconsis-
tent and sometimes contradictory results. For example, some
studies have found associations between PTSD and the do-
pamine receptor D2 gene as well as the nearby ankyrin-
repeat gene ANKK2 (Comings et al., 1996; Young et al., 2002),
whereas other studies have been unable to replicate these
findings (Gelernter et al., 1999). Similarly, reports of associa-
tion to the 5-HTTLPR polymorphism near the serotonin
transporter SLC6A4 have been inconsistent in magnitude and
environmental interaction, a situation further complicated by
whether studies scored this variant as biallelic or triallelic.
Other investigations have focused on genes in the hypotha-
lamic–pituitary–adrenal axis (FKBP5, GCCR, and CNR1) and
the locus coeruleus–noradrenergic systems (NPY, DBH,
COMT, and GABRA2). Binder reported association with
variants in FKBP5 in African Americans (Binder et al., 2008),
and this was replicated in an independent dataset (Xie et al.,
2010). It is likely that the mixed results of these association
studies arise from variations in the study design and rela-
tively low power. Real progress in understanding the genetic
basis of PTSD and the development of robust diagnostic
genetic tests will likely require the performance of well-
powered genome-wide association studies in multiple racial
and ethnic populations.
Although genetic research has the potential to contribute
significantly to understanding of the PTSD risk, development,
and course, there are also possible treatment implications for
genetic testing among individuals with PTSD. For example,
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genetic testing could potentially be used to match patients
with PTSD to medications, most likely to be effective. Carriers
of genes associated with an increased risk of PTSD could
potentially benefit from preventive strategies, such as choos-
ing professions with a less risk of traumatic event exposure.
However, in general, it has been noted that genetic testing
also carries the potential risk of psychological distress, stig-
matization, and discrimination; and misapplication of pre-
ventive strategies (Mitchell et al., 2010).
As genetic research on psychiatric disorders progresses, the
need to understand the issues involved in genetic counseling
for these disorders increases. With this end in mind, it is im-
portant to consider attitudes toward genetic testing in people
with psychiatric disorders. These attitudes could prove useful
in determining how to utilize and implement genetic research
to best benefit those who are diagnosed with PTSD. In fact, with
the emergence of direct-to-consumer genetic tests that provide
information about genetic risks of psychiatric illness, often
without genetic counseling or information about the scientific
evidence for these results, the need to understand perspectives
of target groups is critical (Mitchell et al., 2010). The authors
are not aware of direct-to-consumer tests of the PTSD risk that
are available as of the submission of this article. However, the
availability of test for other psychiatric disorders and emer-
gence of genetic research findings in PTSD suggest the possi-
bility that direct-to-consumer tests for the PTSD risk could be
developed in the near future. Due to the prominence of support
from friends and family in medical decision making (Arora
et al., 2007) and the implications of genetic testing for family
members’ risk of a disorder that affects the patient, it is also
important to evaluate the attitudes of a support person (e.g.,
spouse or family member) toward genetic testing decisions.
Unfortunately, the perspectives of patients with PTSD and
their families on genetic research have yet to be investigated.
Patient perspectives could be invaluable in helping design
information about genetic testing and use of genetics in in-
forming treatment. Although data on attitudes to genetic
testing in PTSD are lacking, a few studies in samples com-
prised of individuals with other psychiatric disorders are
available. For example, data from a large phone survey indi-
cated that a history of psychiatric illness and a perceived
vulnerability to depression were both related to increased
interest in genetic testing for the risk of depression (Wilde
et al., 2011). Those who endorsed statements about the bene-
fits of genetic testing were more than three times more likely
to indicate interest in receiving genetic testing for depression
risk (Wilde et al., 2011). Among family members of individ-
uals diagnosed with schizophrenia, 83% indicated interest in a
test of genetic risk if it were available (DeLisi and Bertisch,
2006). Another report found that interest in genetic testing
was endorsed by a majority of participants with anxiety dis-
orders (76%), bipolar disorder (83%), schizophrenia (77%),
and depression (87%) (Laegsgaard et al., 2009). There is evi-
dence that favorable attitudes toward genetic testing could
translate into behavior, as people at a familial risk of bipolar
disorder reported an interest in taking action to reduce the
risk of psychiatric disorder (Meiser et al., 2008). In addition, a
study of participants from a genetic study of depression risk
found that 66% chose to learn their individual genotype in-
formation (Wilhelm et al., 2009). Taken together, these studies
suggest that many psychiatric patients, family members of
those with psychiatric disorders, and members of the general
population are interested in receiving genetic testing to esti-
mate their risk for psychiatric disorders. In addition, personal
and family history of psychiatric disorders appears to be rel-
evant to genetic test decision making.
Although the scientific groundwork for genetic counseling
in PTSD requires research, several trends provide insights
into the type of evidence that might be available to patients in
the foreseeable future. Several candidate genes implicated in
the neurobiology of PTSD have been identified (Cornelis et al.,
2010), and future genome-wide association studies may
identify additional susceptibility genes. Because the risk for
PTSD is multifactorial, and the genetic risk for PTSD is likely
based on many genes, the decisions of patients considering
genetic testing for PTSD will be complex. Once patients con-
sidering genetic testing for the PTSD risk are informed that
test results will not be dichotomous, they might be well ad-
vised to consider the effect that probabilistic test results will
have on their outlook and behavior. This is significant, as
those with a family history of bipolar disorder have reported
that a higher degree of certainty provided by genetic tests is
related to increased interest in genetic testing for the risk of
bipolar disorder (Meiser et al., 2005). Even in genetic testing
with a high degree of certainty, uptake in genetic testing has
been low. In individuals at a risk for Huntington’s disease,
only *10–20% of those approached for genetic testing request
the procedure (Meiser and Dunn, 2000). Further, the stigma
linked to psychiatric disorders such as PTSD significantly
alters treatment decision making (Gould et al., 2007). These
concerns might also influence attitudes and behaviors related
to genetic testing. While the influence of genetic models of
psychiatric disorder etiology has several possible conse-
quences, preliminary research using interviews of a small
sample of individuals at a familial risk of bipolar disorder has
found that they believed a genetic contribution to bipolar
disorder decreased its associated stigma (Meiser et al., 2005).
However, subsequent research revealed that a genetic model
of bipolar disorder was associated with increased stigma, but
only in the family members of those with bipolar disorder
who had not been diagnosed with bipolar disorder them-
selves. The latter result could be due to the stronger associa-
tion with the family member with bipolar disorder brought on
by a genetic model of psychiatric disorders (Meiser et al.,
2007). In contrast, respondents in a phone survey reported
that a genetic link with depression would increase stigma
(Wilde et al., 2011). Given the stigma associated with psychi-
atric disorders, research is needed to more fully appreciate the
ultimate effect of genetic research in this patient group.
Genetic research in psychiatric disorders ultimately aims
to benefit patients through the use of personalized medicine,
the selection of optimal treatment for a given patient based
on their genetic profile. This could have implications for
several forms of treatment, including medications and psy-
chotherapy. In addition, it is possible that gene therapy will
be developed for psychiatric disorders. However, the current
treatment implications for patients with PTSD would focus
primarily on psychoeducation and planning. For example,
a genetic component of a patient’s PTSD might ameliorate
some of the self-blame and guilt that often accompany PTSD.
In addition, patients with a genetic profile that is associated
with a low risk of PTSD might be relieved to know that their
children are not at increased risk. Patients with a higher-risk
genetic profile might be comforted by knowing that higher
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risk is far different from a genetic certainty, and that PTSD
might be prevented for their children by educating them
about common reactions to trauma and the importance of
seeking treatment after potentially traumatic events.
The current study was designed to examine attitudes to-
ward genetic testing among those with PTSD. U.S. veterans
with PTSD as well as their social support companions were
surveyed and compared to a group of veterans with no psy-
chiatric disorders to identify concerns that could influence
implementation of genetic testing in this group. This report
describes the results of this survey and explores the role of
knowledge of genetics in attitudes toward genetic testing.
Based on the increased interest in genetic testing for depres-
sion in those with a history of psychiatric illness or perceived
vulnerability to depression (Wilde et al., 2011), we hypothe-
sized that veterans with PTSD would report more favorable
attitudes toward genetic testing.
Methods
Participants and procedures
Afghanistan/Iraq-era veterans and their support compan-
ions completed self-report questionnaires, and veterans
participated in a clinical psychiatric interview. A total of 146
veterans participated in the study, with 146 corresponding
companions who were identified as a primary member of
the veteran’s social support. This study was approved by the
Durham Veterans Affairs Medical Center Institutional Re-
view Board. To be eligible, participants had to have served in
the military since October 2001 and be between ages 18 and
65. Veterans’ companions were selected by the veterans and
could be a relative (spouse, life partner, parent, grandparent,
sibling, uncle, or aunt) or a close friend. Participant socio-
demographic characteristics and descriptive statistics for
major study measures are presented in Table 1, along with
frequencies of relationships of companions to veterans.
Participants were recruited from the registry of the Mental
Illness Research, Education, and Clinical Center (MIRECC)
at the Durham Veterans’ Administration Medical Center.
Veterans who consented to be contacted for future studies
through the volunteer research Iraq/Afghanistan-era veteran
registry of the MIRECC were recruited using the Dillman
method (Dillman et al., 2009), which includes sending a series
of three invitational letters. The letters explained the nature
and the purpose of the research, the study procedures, stan-
dard protections for human subjects, and risks and benefits
of the study, and invited veterans to contact a research coor-
dinator for additional information.
Veterans who agreed to participate came in for a session at
the laboratory in which the veteran and their identified
companion provided informed consent and completed self-
report questionnaires. Veterans completed the Clinician Ad-
ministered PTSD Scale to determine the PTSD status (CAPS)
(Blake et al., 1995), and the Structured Clinical Interview
for DSM-IV (SCID) (First et al., 2002) to diagnose other pos-
sible Axis I disorders. Both of these interviews have demon-
strated excellent reliability and validity in clinical settings
(Weathers et al., 2001), and the Fleiss kappa across inter-
viewers for PTSD diagnosis was 1.0. Veterans’ support com-
panions did not complete diagnostic interviews. Diagnostic
interview data were used to sort participants into a current
PTSD group and a control group with no current Axis I psy-
chiatric disorders.
Measures
Knowledge of PTSD test. This measure contains 15 true/
false and multiple-choice tests assessing general under-
standing of PTSD (Pratt et al., 2005). The test includes ques-
tions on traumatic stress and recognition of PTSD symptoms
and treatment methods. In another study, after a brief psy-
choeducational intervention for PTSD, this measure noted an
increase in understanding of PTSD (Pratt et al., 2005).
Survey of knowledge of genetics. This measure asks
participants to rate as True or False a series of 16 statements
Table 1. Sociodemographic and Attitude Variables for Veterans and Their Companions
Variable PTSD (n = 76) Control (n = 70) Test statistics
Veterans
Age (M, SD) 38.93 (9.76) 44.19 (9.92) t = - 3.19a
Years of education (M, SD) 13.85 (3.04) 14.16 (4) t = - 0.51
Gender (N, %) male seven missing 58 (81.69%) 57 (83.82%) v2 = 0.11
Racial minority (N, %) 47 (61.84%) 46 (65.71%) v2 = 0.24
Employed (N, %) 67 (88.16%) 66 (94.29%) v2 = 1.69
Married (N, %) 43 (60.56%) 49 (72.06%) v2 = 2.05
Veterans’ companions
Age (M, SD) 41.18 (13.67) 44.49 (11.56) t = - 1.57
Years of education (M, SD) 2.17 (0.80) 1.88 (0.77) v2 = 5.50
Gender (N, %) male 16 (21.05%) 8 (11.59%) v2 = 2.34
Racial minority (N, %) 43 (58.11%) 47 (67.14%) v2 = 1.25
Relationship to Vet (N, %) PTSD (N = 76) Control (N = 70) v2 = 3.39
Spouse 46 (60.53%) 45 (64.29%)
Sibling 4 (5.26%) 5 (7.14%)
Relative 6 (7.89%) 9 (12.86%)
Parent 13 (17.11%) 6 (8.57%)
Friend 7 (9.21%) 5 (7.14%)
ap < 0.05.
PTSD, posttraumatic stress disorder; SD, standard deviation.
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about genetics. The measure is designed to assess the partic-
ipant’s level of knowledge about the relationship of genes to
diseases and the relationships among genes, chromosomes,
cells, and the body (Calsbeek et al., 2007). It includes state-
ments such as ‘‘A gene is a disease,’’ ‘‘Healthy parents can
have a child with a hereditary disease,’’ and ‘‘All serious
diseases are hereditary.’’ A summary score of correctly an-
swered items was calculated. Missing items were scored as
incorrect. Previous research on this measure has resulted in
good reliability (Cronbach’s alpha = 0.86).
Survey of attitudes toward genetic testing. This is a
13-item questionnaire assessing attitudes related to major
issues raised in response to genetic testing, including medical
aspects of genetic testing, the pros and cons of testing, and the
consequences for relatives, daily life, insurance, and job op-
portunities (Morren et al., 2007). Items are rated on a 5-point
scale ranging from 1 = totally disagree to 5 = totally agree. Of
the 13 statements, six express favorable attitudes toward ge-
netic testing, and seven express reserved attitudes toward
genetic testing. Preliminary research has supported the factor
structure of this measure (Morren et al., 2007). A summary
score is calculated by reverse coding the reserved attitude
items and then summing the item scores.
Perceived benefits/limitations of genetic testing for
PTSD. This is a 19-item measure [adapted from Meiser et al.
(2008)] on which participants rated the importance of several
potential implications of genetic testing on a 5-point scale
ranging from ‘‘Not at all Important’’ to ‘‘Extremely Im-
portant.’’ The measure was developed from participant-
generated benefits and limitations of genetic testing provided
during qualitative research (Meiser et al., 2005). In the limited
research using this measure, Cronbach’s alpha has been high
(a = 0.88–0.90). A summary score was calculated by reverse
coding the limitation items and then summing the item scores.
Statistical analyses
To describe sample characteristics and facilitate normative
comparisons, we calculated frequencies, means, and standard
deviations for the sample as a whole and for the PTSD group
and the non-PTSD group separately. These descriptive sta-
tistics were calculated for sociodemographic variables,
knowledge of genetics, and genetic attitudes. To evaluate the
association of PTSD with attitudes toward genetic testing, we
first calculated independent sample t-tests. To account for
the potential influences of demographic variables, we calcu-
lated a multivariate linear regression equation with age, racial
minority status, gender, and years of education as covariates.
We also examined the effects of PTSD on attitudes toward
genetics across different levels of age, education, and racial
minority status.
Results
Table 1 presents veteran and social support companion
sociodemographic statistics by the PTSD status, as well as
frequencies for the relationships between veterans and their
social support companion. The PTSD group was younger
than the non-PTSD group. Summary scores on measures of
knowledge of genetics and attitudes toward genetics are
presented in Table 2. The knowledge of genetics scores of the
PTSD group (M = 12.12, SD = 1.98) and the control group
(M = 12.20, SD = 1.79) exceed that of published results from
samples of participants with asthma (M = 9.0, SD = 4.0), dia-
betes mellitus (M = 7.1, SD = 3.8), and cardiovascular disease
(M = 6.3, SD = 3.5). In addition, the PTSD group had signifi-
cantly less-favorable attitudes toward genetic testing on both
the survey of attitudes toward genetic testing [t (1) = - 4.05,
p < 0.001] and the perceived benefits/limitations of genetic
testing for PTSD [t (1) = - 2.36, p = 0.020]. Proportions of par-
ticipants endorsing individual items on the genetic attitude
measures are presented in Tables 3 and 4, presented by the
PTSD status. Knowledge of genetics and attitudes toward
genetic testing in veterans’ social support companions was
not significantly different as a function of the veteran’s
PTSD status.
Consistent with summary score results on the survey of
attitudes toward genetic testing, veterans with PTSD were
less likely to endorse several of the items describing favorable
attitudes toward genetic testing for PTSD and more likely to
endorse reserved attitudes. A similar pattern was noted on the
perceived benefits/limitations of genetic testing for PTSD, on
which veterans with PTSD were less likely to endorse state-
ments describing benefits of genetic testing for PTSD and
more likely to endorse limitations.
To further examine the influence of sociodemographic
variables on attitudes toward genetic testing, we analyzed
attitudes at different levels of age, Caucasian-versus-racial
minority, gender, and several levels of education for both
PTSD and non-PTSD participants. Results of these analyses
are presented in Table 5. Because the PTSD group was
younger, we conducted multivariate analyses with age as a
covariate. In addition, based on a previous research identi-
fying knowledge of genetics as a significant factor in attitudes
toward genetic testing (Calsbeek et al., 2007), we also used
genetic knowledge as a covariate. In these models, the pres-
ence of PTSD remained significantly related to less-favorable
attitudes toward genetic testing [b = - 0.30, t (1) = - 3.60,












12.12 (1.98) 12.20 (1.79) - 0.26
PTSD knowledge
(M, SD)
11.41 (2.46) 11.76 (2.27) - 0.89
Genetic attitude
(M, SD)
43.26 (5.92) 47.2 (5.76) - 4.05a
Benefits/limitations
(M, SD)




12.08 (1.87) 12.01 (2.33) 0.18
PTSD knowledge
(M, SD)
11.08 (2.77) 11.11 (2.80) - 0.08
Genetic attitude
(M, SD)
43.22 (5.85) 46.77 (6.02) - 3.59
Benefits/limitations
(M, SD)
41.58 (7.54) 41.55 (7.06) 0.02
ap < 0.05.
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p < 0.001) and lower scores regarding benefits/limitations
[b = - 0.19, t (1) = - 2.17, p = 0.031).
Discussion
This report provides the first data on attitudes toward ge-
netic testing in veterans with PTSD. Compared to veterans
without PTSD, veterans with PTSD were less likely to endorse
favorable attitudes toward genetic testing and also more
likely to endorse reserved attitudes. Both groups had similar
scores on the knowledge of genetics measure. This suggests
that differences in genetic attitudes were not due to the lack of
knowledge about genetics, and that imparting more knowl-
edge to patients with PTSD is likely insufficient to increase
favorable perceptions of genetic testing.
Given the high levels of interest in genetic testing endorsed in
patients with other psychiatric disorders and in the general
population, it is noteworthy that this sample of veterans with
PTSD endorsed less-favorable attitudes. Although education
about genetics has some promise as a method of informing
decision making, attitude differences in our sample were not
explained by baseline differences in age or knowledge of
Table 3. Proportions of Participants Endorsing Agree or Totally Agree
for Items on the Attitudes Toward Genetic Testing Questionnaire
Attitudes toward genetic testing
Non-PTSD (%) PTSD (%)
Favorable attitudes
1. I think that the development of DNA research is a positive medical progress. 96 83a
3. I would inform my children about the results of a DNA test for a specific disease. 83 78
5. I want to know whether my disease is hereditary. 91 79a
7. I approve of using DNA testing for early detection of diseases. 94 82a
11. I would inform my siblings about the results of a DNA test for a specific disease. 84 68a
12. I don’t worry about the consequences of DNA testing for the chances of finding a job. 58 46a
Reserved attitudes
2. If I had a DNA test done, my family need not know about the result. 32 36
4. The idea of a DNA test frightens me. 6 13a
6. I worry about the consequences of DNA testing for being able to take out insurance. 25 42a
8. The possibility of a DNA test will change one’s future. 58 54
9. As long as a disease cannot be treated, I don’t want a DNA test. 6 17a
10. I don’t want a DNA test to tell me that I am at risk for a certain disease. 10 14a
Complete questionnaire total score (M, SD) 43.26 (5.92)a 47.2 (5.76)a
Data on this questionnaire were missing for one non-PTSD participant, so proportions were calculated on the remaining 69 participants.
ap < 0.05.
Table 4. Percentage of Participants Endorsing Statements as Quite Important
or Extremely Important on Perceived Benefits and Limitations
of Genetic Testing for Posttraumatic Stress Disorder Questionnaire
Perceived benefits and limitations of genetic testing for PTSD
Non-PTSD (%) PTSD (%)
Benefits
1. Helps my doctor decide the best medication for me. 69 63
2. Helps research into PTSD. 71 67
3. Helps people who have genetic risk avoid stressors/traumatic events. 70 64
4. Can help prevent PTSD. 67 59
5. Allows PTSD to be diagnosed earlier. 77 68
6. Can help me plan for the future. 71 62
7. Helps me know if I am at risk 77 66
Limitations
8. Could lead to discrimination by employers. 57 70
9. Could lead to insurance discrimination. 61 71
10. Could mean that people who are genetically at risk for PTSD may be more
likely to feel vulnerable.
56 55
11. Could increase worry in people who have a genetic risk who may never
develop PTSD.
51 54
12. Could mean living with uncertainty if genetic testing showed a risk for PTSD. 49 61
13. Could increase stigma because of labeling. 57 66
Total score (M, SD) 39.91 (7.17)a 42.5 (6)a
ap < 0.05.
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genetics. Previous research on reasons for reserved attitudes
toward genetic testing has identified the trust of researchers
and an expectation of being better able to fight the disorder in
light of genetic information as significant predictors of intention
to seek testing in patients with psychiatric disorders (Laegs-
gaard et al., 2009). However, patients with PTSD often struggle
to trust others, especially those in authority (Resick et al., 2008),
and clear options for improved treatment of PTSD in light of
genetic testing information are still in development. Although
the intention to seek genetic testing in patients with psychiatric
disorders has also been linked with parenthood, something
with clear relevance for some patients with PTSD, the presence
of clear implications for PTSD treatment could result in more-
favorable attitudes in these patients. Less-favorable attitudes
toward genetic testing in PTSD have the potential to influence
medical decision making. It is unknown whether these attitudes
are a result of having PTSD or whether these attitudes may
precede the development of PTSD. The possibility of PTSD
symptoms preventing individuals from choosing genetic test-
ing is potentially concerning, as it could impair the ability of
those who might be most in need of this testing from receiving
the intended benefits. Future research could focus more closely
on intrinsic factors such as trust, attitudes toward medical care
or treatment providers, and self-efficacy regarding actions to
take in light of information provided by genetic testing.
Patient attitudes toward genetic testing are important in
PTSD, because those at risk can utilize a number of behaviors
and strategies to prevent and address PTSD. This is in contrast
to genetic illnesses with fewer preventive actions (e.g., Hun-
tington’s disease). As genetic testing for the risk of PTSD
progresses, it will be important to develop preventive treat-
ments for PTSD. These would greatly improve the ultimate
effect of genetic testing for PTSD risk, because those at risk
would have available behaviors to undertake in response
to test results, indicating an increased genetic risk of PTSD.
Currently, individuals at risk could enact behaviors such as
choosing not to enter into professions with higher traumatic
stress frequency, like military service or law enforcement, or
learning about common reactions to trauma and being pre-
pared to seek treatment if trauma reactions do not resolve
quickly.
The findings of this study are limited in that it is unknown
whether (1) attitudes would extend to behaviors for genetic
testing and (2) results would generalize to nonveterans. It will
be important to build on these findings by determining which
factors are related to genetic attitudes in this group and re-
searching the modifiability of these attitudes through inter-
vention. In addition, genetic research in PTSD is a field of
research that is still in an early stage of development. At this
point, individual genetic polymorphisms have relatively
small associations with an increased PTSD risk, though recent
estimates place the overall contribution of genetic factors to
PTSD at *30% (Skelton et al., 2012). There are also important
ethical considerations in psychiatric research, including the
Table 5. Summary of Genetic Attitudes by Posttraumatic Stress
Disorder Status and Sociodemographic Groups
Non-PTSD PTSD
Mean (SD) Mean (SD) Effect size semipartial g2
Age
18–35 47.4 (5.1) (n = 16) 42.3 (5.7) (n = 32) 0.136a
36–50 46.5 (5.9) (n = 35) 44.0 (6.5) (n = 35) 0.040
51 + 48.4 (6.1) (n = 18) 41.7 (4.6) (n = 9) 0.251a
Race
Minority 47.8 (5.5) (n = 44) 42.9 (6.3) (n = 40) 0.154a
Caucasian 46.1 (6.1) (n = 25) 39.5 (8.2) (n = 36) 0.041
Gender
Female 48.0 (5.9) (n = 11) 44.2 (5.1) (n = 13) 0.117
Male 47.1 (5.8) (n = 57) 43.2 (6.3) (n = 58) 0.096a
Education
No college (0–12 years) 48.6 (4.8) (n = 16) 42.9 (5.9) (n = 27) 0.206a
Some college (13–15 years) 48.4 (6.1) (n = 24) 43.5 (6.6) (n = 31) 0.132a
College graduate (16 + years) 45.4 (5.7) (n = 29) 43.4 (5.0) (n = 18) 0.033
Perceived benefits and limitations of genetic testing for PTSD
Age
18–35 42.6 (4.5) (n = 16) 39.8 (7.4) (n = 32) 0.041
36–50 43.0 (6.5) (n = 36) 40.0 (5.8) (n = 35) 0.056a
51 + 41.5 (6.3) (n = 18) 40.0 (11.4) (n = 9) 0.008
Race
Minority 42.9 (6.2) (n = 44) 40.3 (6.2) (n = 40) 0.045
Caucasian 41.8 (5.7) (n = 26) 39.54 (8.2) (n = 36) 0.024
Gender
Female 41.2 (7.2) (n = 11) 40.8 (5.5) (n = 13) 0.001
Male 42.8 (5.8) (n = 57) 39.9 (7.7) (n = 58) 0.044a
Education
No college (0–12 years) 42.9 (4.6) (n = 17) 39.5 (7.6) (n = 27) 0.060
Some college (13–15 years) 44.0 (5.6) (n = 24) 41.5 (5.5) (n = 31) 0.049
College graduate (16 + years) 41.0 (6.8) (n = 29) 37.7 (8.6) (n = 18) 0.045
ap < 0.05.
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possibility of future discrimination in insurance, employment,
or education (Hoop, 2008). This has potential relevance for
PTSD if high-risk professions begin to test for PTSD risk and
block those with high-risk genetic profiles from pursuing their
chosen profession. Despite these limitations, this study rep-
resents a first step toward understanding veteran perspec-
tives in genetic testing among those with PTSD. It will be
important to continue this research to maximize the beneficial
use of genetic testing in this subpopulation of psychiatric
patients.
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